Optimer shares drop on analyst downgrades

Recs

0

Shares of Optimer Pharmaceuticals Inc. fell Monday as several analysts expressed concern over study results from the company's developing gastrointestinal infection drug, Fidaxomicin.

The stock fell 90 cents, or 7.7 percent, to $10.76 in afternoon trading. Shares have traded between $3.30 and $14.70 over the past 52 weeks.

On Sunday, a study investigator presented positive late-stage study results on the drug candidate at a medical conference in Finland. The results showed the treatment is as effective as ViroPharma Inc.'s Vancocin. The drugs treat a gastrointestinal infection called C. difficile, which causes diarrhea.

The full results of the late-stage study are a followup to results announced in November.

But the company also presented a subgroup analysis from the study, showing Fidaxomicin reduced recurrence rates better than Vancocin in several settings, including inpatient and outpatient, and for people both over and under 65 years of age.

The drug was no more effective at reducing recurrence from the most virulent strain of C. difficile, though.

The sub-results disappointed JMP Securities analyst Liisa Bayko, who downgraded shares to "Market Perform" from "Market Outperform" in a note to investors.

"The antibiotic appears to have a lower rate of recurrence regardless of patient age or inpatient status, however, we are disappointed that there is no difference in patients with the hypervirulent strain," she said.

She recommended investors maintain caution as more information on the key differences between Fidaxomicin and Vancocin are clarified.

Meanwhile, a Needham analyst cut the rating to "Hold" from "Buy".

ViroPharma shares gained 33 cents, or 5.9 percent, to $5.93.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 901438, ~/Articles/ArticleHandler.aspx, 11/9/2009 2:50:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Which Companies Can Buy It Like Buffett?

Related Tickers

11/6/2009 4:00 PM
VPHM $7.66 Down -0.13 -1.67%
ViroPharma, Inc. CAPS Rating: *****
OPTR $12.11 Up +0.32 +2.71%
Optimer Pharmaceut… CAPS Rating: *

Community: Investing Wiki

Term Of The Hour

Speculation: Speculation is a risky bet that could have a large payoff if it works out. The speculative investor attempts to profit from the price fluctuations of real estate, commodities, stocks, or any other type of investment that stands to churn out a profit.

Want to learn more or edit this definition?
Click here to read more!